Cardioprotective effects and underlying mechanism of Radix Salvia miltiorrhiza and Lignum Dalbergia odorifera in a pig chronic myocardial ischemia model

RUI LIN1,2*, JIALIN DUAN1*, FEI MU1#, HAIXU BIAN1, MEINA ZHAO1, MIN ZHOU2, YAO LI2, AIDONG WEN1, YONG YANG3 and MIAOMIAO XI1

1Department of Pharmacy, Xijing Hospital, Air Force Military Medical University, Xi’an, Shaanxi 710032; 2School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046; 3Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, P.R. China

Received January 25, 2018; Accepted August 9, 2018

DOI: 10.3892/ijmm.2018.3844

Abstract. Traditional Chinese medicines, including Radix Salvia miltiorrhiza (SM) and Lignum Dalbergia odorifera (DO) extracts, have historically been used to treat myocardial ischemia and other cardiovascular diseases. The volatile oil of DO (DOO) is one of the main components of DO. The aim of the present study was to assess the cardioprotective effects and possible underlying mechanisms of SM-DOO in pigs with ameroid constriction-induced chronic myocardial ischemia. An ameroid constrictor was placed around the left anterior descending coronary artery of pigs to induce chronic myocardial ischemia. At weeks 2, 6 and 8, myocardial injury markers and blood gas levels were detected. At week 8, coronary angiography, echocardiography and hemodynamics analysis were performed to evaluate myocardial function. Following sacrifice, myocardial tissue was collected and subjected to morphological, histopathological and apoptosis assays. Western blotting was used to detect the protein expression of Bcl-2 associated X (Bax), Bcl-2, Akt, phosphorylated (p)-Akt, glycogen synthase kinase (GSK)-3β and p-GSK-3β. It was revealed that SM-DOO treatment following chronic myocardial ischemia significantly downregulated the expression of myocardial injury markers, ameliorated myocardial oxygen consumption, increased collateralization, reduced regional cardiac dysfunction and limited the extent of myocardial damage. Furthermore, the results of an apoptosis assay revealed that the apoptosis rate was decreased, the expression of Bax decreased and Bcl-2 increased, and the ratio of Bcl-2/Bax was increased. Further experiments indicated that treatment with SM-DOO increased the phosphorylation of Akt and GSK-3β. These findings suggest that SM-DOO treatment ameliorates myocardial injury in a chronic myocardial ischemia model, and that the underlying mechanisms responsible may be associated with the activation of the Akt/GSK-3β signal pathway. Thus, experimental evidence that SM-DOO may be an effective drug for the prevention and treatment of chronic myocardial ischemia in clinical applications has been provided.

Introduction

Myocardial ischemia, which is caused by an imbalance between the myocardial oxygen supply and myocardial oxygen requirement, can induce arrhythmia, cardiac dysfunction, myocardial infarction and sudden death (1). Although there are a number of novel drugs available for the treatment and prevention of myocardial ischemia, the mortality and morbidity continue to increase (2). It was previously reported that apoptosis may be an important step in the pathogenesis of myocardial injury, and exploring anti-apoptotic drugs may provide novel therapeutic opportunities for the treatment of myocardial ischemia (3).

Traditional Chinese medicine (TCM) has been used to treat cardiovascular diseases for more than 1,000 years with significant efficacy and minimal side effects (4). Among the herbs used in TCM, Radix Salvia miltiorrhiza (SM) and Lignum Dalbergia odorifera (DO) have been widely used in clinical and basic laboratory studies for the prevention and treatment of cardiovascular diseases, including in China (5-10). SM, known as Danshen in Chinese, has been used to treat cardiovascular...
diseases, including coronary heart disease, hyperlipidemia and cerebrovascular diseases (11). DO, known as Jiangxiang in Chinese, has been used to treat ischemia, necrosis, swelling, blood disorders and rheumatic pain (12). A number of well-known Chinese medicines for treating cardiovascular disease contain SM and DO, including Guanxin II, Guanxin Danshen capsules, Xiangdan injection and Qishen Yiqi pills. The effect of the combination of SM-DO has been shown to be efficacious in clinical use (13,14); however, there are few studies regarding their action and the underlying mechanisms responsible. In our previous experiment, the cardioprotective effects of SM and DO were evaluated in a rat myocardial ischemia-reperfusion model. The results indicated that combined treatment with SM and DO had significant cardioprotective effects, and that the combination of SM with DO volatile oil (DOO) (SM 5 g/kg/day, DOO 0.5 ml/kg/day) was significantly more effective than SM, DO or DOO alone (15). However, the effects of SM-DOO in chronic myocardial ischemia have yet to be reported.

The aim of the present study was to investigate the cardioprotective effect and potential mechanisms of SM-DOO in a pig model of chronic myocardial ischemia. The major chemical components of SM and DOO were also determined using high-performance liquid chromatography (HPLC) and gas chromatography coupled with mass spectrometry (GC-MS), respectively.

Materials and methods

Materials and reagents. SM extract was purchased from Xi'an Honson Biotechnology Co., Ltd. (Xi'an, China; batch no. 161025). The major components were hydrophilic salvianolic acid and hydrophobic tanshinones, as evaluated by HPLC analysis. DOO was purchased from Jishui Jinhai Natural Perfume Oil Technology Co., Ltd. (Jiangxi, China; batch no. XC20160918) and the major components were evaluated by GC-MS. Standards for danshensu, rosmarinic acid, salvianolic acid B, salvianolic acid A, protocatechuic acid, protocatechuic aldehyde, dihydrotoxinone I, cryptotanshinone, tanshinone IIa, and tanshinone IIb, silicate sodium were purchased from Shanghai ANPEL Laboratory Technologies, Inc. (Shanghai, China; batch no. Q2880010). Acetonitrile was purchased from Perfume Oil Technology Co., Ltd. (Jiangxi, China; batch no. 161025). The major components were hydrophilic salvianolic acid and hydrophobic tanshinones, as evaluated by HPLC analysis. DOO was purchased from Jishui Jinhai Natural Perfume Oil Technology Co., Ltd. (Jiangxi, China; batch no. XC20160918) and the major components were evaluated by GC-MS. Standards for danshensu, rosmarinic acid, salvianolic acid B, salvianolic acid A, protocatechuic acid, protocatechuic aldehyde, dihydrotoxinone I, cryptotanshinone, tanshinone IIa, and tanshinone IIb, silicate sodium were purchased from Shanghai ANPEL Laboratory Technologies, Inc. (Shanghai, China; batch no. Q2880010). Acetonitrile was purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). All other reagents were analysis grade.

Deionized water was prepared using a Milli-Q water purification system (EMD Millipore, Bedford, MA, USA). 2,3,5-triphenyltetrazolium chloride (TTC) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Pig creatine kinase-MB (CK-MB), cardiac troponin I (cTnI), and myoglobin (Myo) ELISA kits were bought from Xitang Biological Technology company (Shanghai, China). Lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) test kits were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All primary antibodies, including Bel-2 associated X (Bax; cat. no. 2772), Bel-2 (cat. no. 2870), Akt (cat. no. 9272), phosphorylated (p)-Akt (cat. no. 9271), glycogen synthase kinase (GSK)-3β (cat. no. 9315), p-GSK-3β (cat. no. 9336) and β-actin (cat. no. 4970), were purchased from Cell Signaling Technologies, Inc. (Danvers, MA, USA). The secondary antibody (anti-rabbit IgG-B; cat. no. sc-53804) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Herbal extraction. SM was dried at 50˚C and ground into powder (<1 mm). SM (150 g) was soaked in 8-fold the volume of water for 30 min at room temperature and extracted for 3 h (1.5 h/reflux), followed by reflux extraction with 75% ethanol. The filtrates were combined, concentrated under reduced pressure and freeze-dried. DOO was isolated by steam distillation for 5 h, with a yield of 0.5% DOO, which was stored at 4˚C.

Preparation of standard solutions. Primary standard solutions of the 10 components were prepared by dissolving the solid standards in methanol. Working mixed standard solutions (40 µg/ml) were prepared by mixing and diluting the stock solution with methanol. The mixed standard solution was filtered through a 0.22-µm membrane before HPLC analysis.

Preparation of herb solutions. SM was dried at a temperature of 50˚C and ground into powder. Subsequently, 0.25 g SM was soaked in 8-fold the volume of water for 30 min at room temperature and extracted for 4 h, followed by ultrasound-assisted extraction for 30 min with 80% methanol. The suspension was filtered, concentrated and diluted to a 50-ml volume with methanol. The solution was filtered through a 0.22-µm membrane prior to HPLC analysis.

An aliquot of 200 µl DOO was diluted in 20 ml of ethyl acetate and dried over anhydrous sodium sulfate. The supernatant was filtered through a 0.22-µm membrane prior to GC-MS analysis.

Chromatographic conditions. HPLC analysis was performed using an Agilent 1260 HPLC system (Agilent Technologies, Santa Clara, CA, USA) and chromatographic separation was accomplished using an Agilent TC-C18 column (4.6x250 mm, 5 µm). The column temperature was set at 30˚C with a 20-µl injection volume. The mobile phase consisted of 0.2% formic acid (v/v) in water (A) and acetoni trile (B). The gradient program used was as follows: 10% B to 30% B (0-15 min), 30% B to 32% B (15-40 min), 32% B to 55% B (40-55 min), 55% B to 67% B (55-65 min), 67% B to 72% B (65-75 min), 72% B to 85% B (75-85 min) and 100% B (85-100 min). The flow rate was set at 0.8 ml/min throughout the analysis, and UV detection was set at 270 nm.

The components of DOO were analyzed using an Agilent 7890A gas chromatograph coupled with an Agilent 5975C mass selective detector (Agilent Technologies). Chromatographic separation was performed using an HP-5MS capillary column (30 m x 0.25 mm x 0.25 µm film thickness, Agilent Technologies). The split ratio was 15:1, and the injection volume was set to 2 µl. The inlet and ion source temperatures were set to 260˚C and 230˚C, respectively. The helium flow rate was set to 1.0 ml/min. The oven temperature was initially 60˚C, followed by a 1.5˚C/min increase to 105˚C for 10 min, then a 1˚C/min increase to 115˚C for 10 min, a 2.5˚C/min increase to 160˚C for 5 min and finally to 260˚C at a heating rate of 20˚C/min. MS was used in full scan mode with the acquisition range set to 30-800 m/z. GC-MS post-run analysis was performed, and the main components were identified using the library of the National Institute of Standards and
injury markers, including cK-MB, LDH, ALT, AST, cTnI and centrifuged at 2,285 x g at 4°C for 15 min. Myocardial samples were collected in heparinized tubes, allowed to clot for 30 min and subsequently the blood was centrifuged, and the supernatant was used for analysis.

Measurement of myocardial injury markers. Blood samples were collected in heparinized tubes, allowed to clot for 30 min and centrifuged at 2,285 x g at 4°C for 15 min. Myocardial injury markers, including CK-MB, LDH, ALT, AST, cTnI and Myo, were measured using assay kits or pig-specific ELISA kits according to the manufacturers’ protocols.

Blood gas analysis. At weeks 2, 6 and 8, pH, PO2 and PCO2 were measured in arterial blood samples taken from the femoral artery (500-700 µl) using pre-heparinized syringes (1,000 IU/ml) and analyzed using an i-STAT 1 blood gas system (Abbott Laboratories, Chicago, IL, USA).

Echocardiography. Echocardiography was performed at the end of the study using a Vivid 9 machine (GE Vingmed Ultrasound AS, Horten, Norway). Left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESD), end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (EF) and fractional shortening (FS) were recorded to assess cardiac function. The FS value was calculated based on the following equation: FS (%) = [(LVEDd-LVESd)/LVEDd] x 100%. Images were stored and analyzed using Echopac software (GE Vingmed Ultrasound AS).

X-ray coronary angiography. X-ray coronary angiography (GE Medical Systems, Milwaukee, WI, USA) with iopromide (Juste SAQF, Madrid, Spain) was performed on all experimental animals to verify the occlusion of the LAD and assess collateral vessel filling at the end of the experiment. The grade of collateral filling was scored using a standard 4-point scale as follows (18): 0 = no collateral filling; 1 = minimal collateral filling; 2 = moderate collateral filling, but less than the contralateral or ipsilateral non-infarct coronary artery; 3 = normal collateral filling compared with the contralateral or ipsilateral non-infarct coronary artery.

Hemodynamic monitoring. The heart rate (HR), mean arterial blood pressure (MAP), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), left ventricular maximum upstroke velocity (+dp/dtmax) and left ventricular maximum descent velocity (-dp/dtmin) were recorded using a pressure transducer (Millar Instruments, Houston, TX, USA) connected to an anesthesia monitor (Philips, Eindhoven, Netherlands).

Morphometric and histopathological examination. Animals were sacrificed by intravenous injection with potassium chloride after the imaging study, and their hearts were explanted. Hearts were serially sliced and incubated with 2% 1,000 IU/ml of 3% H2O2. Images were taken at 400x magnification (Nikon Corporation, Tokyo, Japan), to confirm the successful labeling of apoptotic cells and nuclei. The percentage of TUNEL-positive cells was calculated as the number of apoptotic cells divided by the total number of nuclei x 100.
Western blotting analysis. Myocardial tissues were homogenized in RIPA buffer containing 1% PMSF and 1% protease inhibitor cocktail (Nanjing Jiancheng Bioengineering Institute), and the supernatant was harvested by concentration (18,447 x g at 4˚C for 10 min). The protein concentration was determined based on the BCA method using a Protein Quantitative Analysis kit (Nanjing Jiancheng Bioengineering Institute). The lysates were separated by 10% SDS-PAGE. Following separation, the proteins were transferred onto polyvinyl difluoride membranes, blocked for 1 h at 37˚C with 5% non-fat dried milk, washed 3 times with Tween in Tris-buffered saline, and incubated with primary antibodies against Bax, Bcl-2, Akt, p-Akt, GSK-3β, p-GSK-3β and β-actin (dilution, 1:1,000) overnight at 4˚C. Subsequent to washing 3 times as described above, the membranes were incubated with secondary antibodies (dilution, 1:5,000) at 37˚C for 1 h.
Immunoreactive bands were detected using the enhanced chemiluminescence method and semi-quantified using ImageJ Software version 1.47 (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. Statistical analysis was conducted using GraphPad Prism version 6.02 (GraphPad Software, Inc., La Jolla, CA, USA). All data are presented as the mean ± standard deviation. One-way analysis of variance with Tukey’s multiple comparison post-hoc test was performed to analyze the data. P<0.05 was considered to represent a statistically significant difference.

Results

Evaluation of the chronic myocardial ischemia model and effect of SM-DOO on collateral vessel filling. The ameroid constrictor was used to induce coronary closure. Coronary angiography indicated that the rate of coronary stenosis reached 98-100% 4 weeks after ameroid constrictor implantation, indicating that chronic myocardial ischemia was stably established. As shown in Fig. 2, coronary angiography revealed LAD stenosis with no evidence of collateral vessel filling in the Model group (0.20±0.11); however, collateral filling was observed in the SM-DOO group (1.49±0.31). Collateral scores were significantly increased by the administration of SM-DOO compared with the Model group (P<0.01).

Effect of SM-DOO on myocardial injury markers. As presented in Fig. 3, no differences were observed in cK-MB, LdH, ALT, AST, cTnI and Myo between the 3 groups at week 2. cK-MB, LdH, ALT, AST, cTnI and Myo levels in the Model group were higher compared with the Sham group at weeks 6 and 8. In the Model group, at week 8, the expression of myocardial injury markers was higher compared with at week 6. Conversely, cK-MB, LdH, ALT, AST, cTnI and Myo were significantly decreased in the SM-DOO group compared with the Model group (P<0.05 or P<0.01), demonstrating that SM-DOO ameliorated injury in chronic myocardial ischemia.

Effect of SM-DOO on myocardial oxygen consumption. To investigate whether the cardioprotective effects of SM-DOO were mediated by affecting myocardial oxygen consumption, blood gas was quantified. As presented in Fig. 4, pH, PO₂
and PCO₂ were the same in all 3 groups prior to the induction of chronic myocardial ischemia. By weeks 6 and 8, the arterial pH and PO₂ were markedly lower, while the PCO₂ was higher in the Model group than that in the Sham group (47.13±3.91 vs. 40.57±3.29 mmHg at week 6; 49.05±5.56 vs. 39.46±3.10 mmHg at week 8). Thus, compared with the Model group, SM-dOO markedly ameliorated the effects on pH, PO₂ and PCO₂ induced by myocardial ischemia.

Effects of SM‑DOO on left ventricular function. To assess the cardioprotective effects of SM-dOO, left ventricular function was examined. Compared with the Sham group, the mitral and apical levels in the Model group were reduced, the papillary muscle was thinned, and the left ventricular anterior wall moments were weakened (Table I). Additionally, in the Model group, the echocardiography parameters of LVEdd, LVEds, EDV and ESV were significantly increased, while EF and FS were markedly reduced (P<0.05 or 0.01), whereas MAP, LVSP and +dp/dt max were significantly increased, compared with the Model group (102.17±22.203 vs. 67.07±16.378 mmHg for MAP; 115.52±21.528 vs. 83.20±9.189 mmHg for LVSP; and 2,017.91±548.228 vs. 1,244.58±284.314 mmHg/sec for +dp/dt max; P<0.05).

Effects of SM‑DOO on myocardial damage. After the pigs were sacrificed, hearts were collected for morphometric and histopathological analysis. Cardiac sections were stained with TTC to compare the infarct size between the 3 groups. As shown in Fig. 7A, the mean infarct size in the Model group was larger than that in the SM-DOO group. The infarct size was

Table I. Movement of the left ventricular anterior wall at the mitral level, papillary muscle level and apical level.

| Group   | Mitral level | Papillary muscle level | Apical level |
|---------|--------------|------------------------|--------------|
|         | End-systolic | End-diastolic          | End-systolic | End-diastolic | End-systolic | End-diastolic |
| Sham    | 1.067±0.121  | 0.773±0.103            | 1.100±0.141  | 0.750±0.084  | 1.100±0.126  | 0.700±0.063  |
| Model   | 0.800±0.063  | 0.550±0.055            | 0.850±0.138  | 0.583±0.075  | 0.767±0.103  | 0.533±0.052  |
| SM-dOO  | 0.950±0.105  | 0.683±0.075            | 1.067±0.105  | 0.717±0.075  | 0.950±0.085  | 0.667±0.103  |

All values are presented as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. Sham group; *P<0.05 vs. Model group. SM, Radix Salvia miltiorrhiza; DOO, Lignum Dalbergia odorifera volatile oil.
significantly decreased in the SM-DOO group (5.91±1.25%) compared with the Model group (12.93±1.68%; P<0.01; Fig. 7B). Thus, SM-DOO treatment reduced the myocardial infarct size after chronic myocardial ischemia.

As presented in Fig. 7C, the myocardium was H&E stained for histological examination. Myocardial tissues in the Sham group exhibited no abnormalities. As expected, chronic myocardial ischemia induced evident injury to the myocardial structure, including chronic inflammatory cells, edema in the myocardial fibers and ruptured myocardial fibers in the Model group. Myocardial alterations following chronic myocardial ischemia, in particular, disruption to the myocardial fibers, were significantly ameliorated by SM-DOO.

Effects of SM-DOO on myocardial apoptosis and Bax and Bcl-2 expression. As shown in Fig. 8A, more apoptotic cells were observed in the Model group compared with the Sham group. The percentage of TUNEL-positive cells was significantly lower in the SM-DOO group (19.78±2.53%) compared with the Model group (28.20±5.33%), as shown in
Fig. 8B (P<0.01). To further examine the potential mechanisms of the anti-apoptotic effect of SM-dOO, the expression of Bax and Bcl-2 was determined. As shown in Fig. 8C, D and E, the expression of Bax was significantly increased and Bcl-2 was significantly decreased in the Model group. In addition, the Bcl-2/Bax ratio was significantly decreased in the Model group (Fig. 8F; P<0.01). Thus, treatment with SM-dOO ameliorated the effects of chronic myocardial ischemia on apoptosis.

Effect of SM-dOO on Akt and GSK-3β activation. To investigate the signaling pathways involved in the cardioprotective effects of SM-dOO, the expression of Akt, p-Akt, GSK-3β and p-GSK-3β was determined. As shown in Fig. 9, compared with the Sham group, the expression of p-Akt and p-GSK-3β was slightly increased, while Akt and GSK-3β levels were not altered in the Model group. Compared with the Model group, the SM-dOO group had significantly higher levels of p-Akt/Akt and p-GSK-3β/GSK-3β (P<0.01), indicating that SM-dOO administration markedly increased p-Akt and p-GSK-3β levels.

Detection of SM and DOO components by chromatography. By comparing the retention times of mixed standard solutions with SM (Fig. 10A), 8 components were identified as danshensu, rosmarinic acid, salvianolic acid B, salvianolic acid A, tanshinone IIα silate sodium, dihydrotanshinone I, cryptotanshinone and tanshinone IIα by chromatography (Fig. 10B). The main components of SM were salvianolic acid B (18.67%), cryptotanshinone (11.83%) and tanshinone IIα (10.55%). A total of
9 chemical components of DOO were detected by GC-MS and identified by NIST Database retrieval, as shown in Table II. The major components of DOO were nerolidol (22.52%), caryophyllene oxide (12.70%), α-santalol (9.01%) and β-farnesene (5.16%). The total ion current (TIC) of DOO is given in Fig. 10C.

Discussion

Myocardial ischemia has become one of the most common cardiovascular diseases, and it is difficult to treat in the clinic. The beneficial effects of SM-DOO in the prevention and treatment of heart disease have been demonstrated. However, little has been reported regarding the potential cardioprotective effects of SM-DOO in chronic myocardial ischemia. To address this problem, a clinically relevant animal model was used in the present study to evaluate the cardioprotective effects of SM-DOO in chronic myocardial ischemia.

Small animal models have been extensively used in cardiovascular research (19-21). However, they bear only a partial resemblance to humans, which may not translate to clinical trials (22). Pig models are widely used to research cardiovascular disease because of the similarities between pig and human hearts, such as cardiac anatomy and function, hemodynamics, coronary circulation, drug dosing, pharmacokinetics and a lack of preexisting collateral circulation (23). An ameroid constrictor is a stainless steel jacket with a casein bar in its central lumen. Dehydrated casein has a tendency to absorb fluid and swell, thus gradually leading to the chronic myocardial ischemia by obstructing the coronary...
artery (24-27). In the present study, an X-ray coronary angiography demonstrated that the chronic myocardial ischemia model was stably established.

CK-MB, LDH, Myo and cTnI levels are considered to be important indicators of myocardial damage, and are significantly increased by blockage of the LAD (28-32). In addition, AST and ALT have previously been used to diagnose coronary heart disease (33,34). The elimination and release of myocardial injury markers occurred at different times, suggesting that the combined analysis of myocardial injury markers may

Figure 10. Representative chromatograms of the identified components in (A) mixed standard solutions of SM and (B) the SM extract, including 1. danshensu, 2. protocatechuic acid, 3. protocatechuic aldehyde, 4. rosmarinic acid, 5. salvianolic acid B, 6. salvianolic acid A, 7. tanshinone IIA silate sodium, 8. dihydrotanshinone I, 9. cryptotanshinone and 10. tanshinone II A. (C) Total ion chromatogram of DOO, as determined by gas chromatography coupled with mass spectrometry. SM, Radix Salvia miltiorrhiza; DOO, Lignum Dalbergia odorifera volatile oil.
provide more precise information to influence therapeutic decisions (35). Thus, sensitive myocardial injury markers, including CK-MB, LDH, ALT, AST, cTnI and Myo, were measured to determine whether SM-DOO alleviated the degree of myocardial ischemia. As expected, SM-DOO significantly reduced changes in these markers, demonstrating an amelioration of myocardial injury. Furthermore, the echocardiographic (LVEDd, LVEDs, EDV, ESV, EF and FS) and hemodynamic (MAP, HR, LVSP, LVEDP, +dp/dt max and -dp/dt max) parameters suggested that SM-DOO had a beneficial effect on preventing the impairment of cardiac function. In addition, LAD occlusion leads to myocardial injury and metabolic acidosis, decreasing the levels of PO2 and increasing PCO2 (29,36). In the present study, SM-DOO significantly prevented these changes, ameliorating myocardial oxygen consumption. Severe myocardial ischemia is associated with microstructural abnormalities in the myocardium (37). Pre-treatment with SM-DOO decreased the infarct size and reduced the extent of myocardial damage, supporting that conclusion that SM-DOO provided cardioprotective effects.

The results of the present study have determined that SM-DOO has a cardioprotective effect against chronic myocardial ischemia. Next, the potential mechanisms of these effects were explored. Apoptosis plays an important role in cardiac injury and has become a focus of research (38). The expression of several apoptosis-related genes is altered in ischemic tissue, including Bax and Bcl-2, which play important roles in apoptosis (39). The Bcl-2 family members are key regulators of physiological and pathological apoptosis, including cell death promoters such as Bax and Bcl-2 associated agonist of cell death, and cell death inhibitors such as Bcl-2, Bcl-X and Mcl-1 (40). Changes in the Bcl-2/Bax ratio leads to the induction of apoptotic cell death (41). In the present study, the anti-apoptotic effects of SM-DOO may be mediated by inhibiting the upregulation of Bax and downregulation of Bcl-2. This finding is consistent with the results of the TUNEL assay. These results suggest that SM-DOO may exert its cardioprotective effect against myocardial injury following chronic myocardial ischemia by preventing apoptosis.

The PI3K/Akt pathway is particularly important in mediating myocardial cell survival. Studies have shown that activation of the PI3K/Akt signaling pathway is essential for anti-apoptotic and cardioprotective effects (42,43). GS-3 is a serine/threonine kinase with versatile cellular functions in the heart, including in gene expression, hypertrophy and apoptosis (44). GS-3β is active in cardiomyocytes unstimulated by ischemia and ischemia/reperfusion, and sensitizes cells to death-promoting insults, which may be an underlying mechanism of cardioprotection (45). Akt phosphorylates and subsequently inactivates GS-3β, which contributes to the attenuation of myocardial injury (46). To investigate the involvement of the PI3K/Akt signaling pathway on the cardioprotective effects of SM-DOO treatment, the expression of Akt and GS-3β was determined using western blotting. As shown in the results, pretreatment with SM-DOO significantly increased the relative p-Akt and p-GSK-3β levels compared with the Model group. These findings suggest that the PI3K/Akt/GSK-3β signaling pathway may be involved in the cardioprotective effects of SM-DOO in a chronic myocardial ischemia model. However, further studies utilizing an inhibitor of PI3K/Akt are required to validate the involvement of this pathway.

The chemical composition of SM includes water-soluble and lipid-soluble components (47,48). Using HPLC analysis, 8 components of SM were identified by comparing its retention time with the standards. The main components of SM were salvianolic acid B, cryptotanshinone and tanshinone IIα. DOO was also analyzed using the established GC-MS method. The majority of the components, including pinene, terpinolene, eucalyptol, eugenol, β-farnesene, α-santalol, α-farnesene, nerolidol and carpyhyllene oxide, were identified by performing a similarity match with the NIST Database. Studies have demonstrated that various chemical components of SM, such as danshensu, salvianolic acid B, salvianolic acid A, rosmarinic acid and tanshinone IIA, have anti-apoptotic activities (49-52). In addition, recent research indicates that tanshinone IIA, dihydrotanshinone I, danshensu, salvianolic acid B and salvianolic acid A play a protective role by regulating GS-3β (53-56). However, there are few studies regarding whether the chemical components of DOO achieve a protective effect by regulating GS-3β. We plan to explore the effects of active chemical constituents of SM-DOO against chronic myocardial ischemia in the future.

In conclusion, pretreatment with SM-DOO may ameliorate cardiac injury resulting from chronic myocardial ischemia. Myocardial injury markers (CK-MB, LDH, ALT, AST, cTnI and Myo), markers of myocardial oxygen consumption (pH, PO2 and PCO2), metrics of left ventricular function (LVEDd, LVEDs, EDV, ESV, EF, FS, MAP, HR, LVSP, LVEDP, +dp/dtmax and -dp/dtmax ) and indicators of myocardial tissue damage (TTC, H&E, TUNEL and western blotting) revealed the effects of SM-DOO against chronic myocardial ischemia. Furthermore, the cardioprotective effects of SM-DOO may be partly mediated via activation of the PI3K/Akt/GSK-3β signaling pathway. The results of the present study may help to improve our understanding of the molecular mechanisms underlying the cardioprotective effects of SM-DOO, and provide a basis for the use of SM-DOO as an effective drug for the prophylaxis and treatment of chronic myocardial ischemia.

Acknowledgements

The authors would like to thank Beijing Key Laboratory of Pre-clinical Research and Evaluation for Cardiovascular Implant Materials (Fuwai Hospital, Chinese Academy of Medical Sciences) for providing the experimental animals and platform.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81470174 and 31771265).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.
Authors' contributions

The present study was performed with collaboration between all authors. MX, YY and AW defined the research theme and revised the manuscript critically. RL, JD and FM designed the methods and experiments, performed the laboratory experiments and wrote the paper. HB, MNZ, MZ and YL collected and analyzed the data, and interpreted the results. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The Animal Welfare and Ethics Committee of Fuwai Hospital, Chinese Academy of Medical Sciences approved all experiments [approval no. 0072-1-27-HX (F)].

Competing interests

The authors declare that they have no competing interests.

References

1. Shimokawa H and Yasuda S: Myocardial ischemia: Current concepts and future perspectives. J Cardiol 52: 67-78, 2008.
2. Lv Y, Liu X, Yan S, Liang X, Yang Y, Dui W and Zhang W: Metabolomic study of myocardial ischemia and intervention effects of Compound Danshen Tablets in rats using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Pharm Biomol Anal 52: 129-135, 2010.
3. Xu T, Wu X, Chen Q, Zhu S, Liu Y, Pan D, Chen X and Li D: The anti-apoptotic and cardioprotective effects of salvinialonic acid on rat cardiomyocytes following ischemia/reperfusion by DU85-mediated regulation of the ERK1/2/JNK pathway. PLoS One 9: e102292, 2014.
4. JianXin C, Xue X, ZhongFeng L, Kuo G, FeiLong Z, ZhiHong L, Xian W and HongCai S: Qishen Yiqi Drop Pill improves cardiac function after myocardial ischemia. Sci Rep 6: 24383, 2016.
5. Zhang Y, Shi P, Yao H, Shao Q and Fan X: Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishen yiqi pills) in rats. Curr Drug Metab 13: 510-523, 2012.
6. Wu SD, Wang J, Chen SC, Xu JB, Zheng Q, Yan YF, Wen TM and Tang YR: Effect of Xiangdan Injection on mRNA expression of endothelial vaso-active factors of patients with coronary heart disease and blood stasis. Zhong Yi Yi Jie Hua Bao 2: 94-96, 2004 (In Chinese).
7. Wang SX, Luo K, Liang J, Fan F, Li H, Zheng JB and Zheng XH: Metabolomics study on the synergistic interaction between Salvia miltiorrhiza and Lignum dalbergiae odoriferae used as ‘Jun-Shi’ herbs in a S. miltiorrhiza recipe. Med Chem Res 20: 16-22, 2011.
8. Sugiyama A, Zhu BM, Takahara A, Satoh Y and Hashimoto K: Cardiac effects of salvia miltiorrhiza/dalbergia odorifera mixture, an intravenously applicable Chinese medicine widely used for patients with ischemic heart disease in China. Circ J 66: 182-184, 2002.
9. Mi F, Duan J, Bian H, Zhai X, Wang P, Lin R, Zhao M, Hu D, Yin Y, Wen A, et al: Metabonomic strategy for the evaluation of Chinese medicine salvia miltiorrhiza and dalbergia odorifera interfering with myocardial ischemia/reperfusion injury in rats. Rejuvenation Res 20: 263-277, 2017.
10. Zhong X, Xiaohao X, Wang S, Luo K, Wei Y and Zheng J: Co-administration of Dalbergia odorifera increased bioavailability of Salvia miltiorrhiza in rabbits. Am J Chin Med 35: 831-840, 2007.
11. Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359, 2005.
12. Liu R, Ye M, Guo H, Bi K and Guo DA: Liquid chromatography/electrospray ionization mass spectrometry for the characterization of twenty-three flavonoids in the extract of Dalbergia odorifera. Rapid Commun Mass Spectrom 19: 1557-1565, 2005.
13. Tu J and Song K: Curative effect observation on Xiangdan injection in the treatment of coronary artery disease. Chin Med Pharm 22: 110-111, 2011 (In Chinese).
14. Gao F and Huang X: Guanxin II for the management of coronary heart disease. Chin J Integr Med 15: 472-476, 2009.
15. Mu F, Duan J, Bian H, Yin Y, Zhu Y, Wei G, Guan Y, Wang Y, Guo C, Wen A, et al: Cardioprotective effects and mechanism of Radix Salviae miltiorrhizae and Lignum Dalbergiae odoriferae on rat myocardial ischemia/reperfusion injury. Mol Med Rep 16: 1759-1763, 2017.
16. Krishnamoorthy K and Subramaniam P: Phytochemical profiling of leaf, stem, and tuber parts of Solena amplexicaulis (Lam.) Gandhi using GC-MS. Int Sch Res Notices 2014: 567409, 2014.
17. Huang JH, Huang XZ, Chen ZY, Zheng QS and Sun RY: Dose correlation among different animals and health volunteers in pharmacological study. Chin J Clin Pharmacol Therap 9: 1069-1072, 2004.
18. Henriques JP, Zijlstra F, van ‘t Hof AW, de Boer MJ, Dambirk JH, Gosselink M, Hoornje JC and Suryapranata H: Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 107: 2152-2159, 2003.
19. Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, et al: The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism 65: 122-130, 2016.
20. Saito N: Letter by Saito regarding article, ‘Collateral donor artery physiology and the influence of a chronic total occlusion on fractional flow reserve’. Circ Cardiovasc Interv 8: e002794, 2015.
21. Zhao HW, Qin F, Liu XY, Huang X and Ren P: Antiapoptotic mechanisms of Chinese medicine formula, Guan-Xin-Er-Hao, in the rat ischemic heart. Tohoku J Exp Med 216: 309-316, 2008.
22. Seok J, Warren HS, Cuenca AG, Minnirdinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507-3512, 2013.
23. Elmadhun NY, Sae BA, Robich MP, Chu LM, Lassaletta AD and Sellke FW: The pig as a valuable model for testing the effect of resveratrol to prevent cardiovascular disease. Ann NY Acad Sci 1290: 130-135, 2013.
24. Ikonen TS, Pitäilä T, Virtanen K, Lappalainen K, Zhang Y, Shi P, Yao H, Shao Q and Fan X: Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishen yiqi pills) in rats. Curr Drug Metab 13: 510-523, 2012.
25. Qin F and Huang X: Guanxin II for the management of coronary heart disease and blood stasis. Zhong Xi Yi Jie He Xue Bao 2: 94-96, 2002.
26. Henriques JP, Zijlstra F, van ‘t Hof AW, de Boer MJ, Dambirk JH, Gosselink M, Hoornje JC and Suryapranata H: Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 107: 2152-2159, 2003.
27. Seok J, Warren HS, Cuenca AG, Minnirdinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507-3512, 2013.
33. Elizondo-Montemayor L, Ugalde-Casas PA, Lam-Franco L, Bustamante-Careaga H, Serrano-González M, Gutiérrez NG and Martínez U: Association of ALT and the metabolic syndrome among Mexican children. Obes Res Clin Pract 8: e79-e87, 2014.

34. Xu Q, Higgins T and Cembrowski GS: Limiting the testing of AST: A diagnostically nonspecific enzyme. Am J Clin Pathol 144: 423-426, 2015.

35. Solymoss BC, Bourassa MG, Fortier A and Théroux P: Evaluation and risk stratification of acute coronary syndromes using a low cut-off level of cardiac troponin T, combined with CK-MB mass determination. Clin Biochem 37: 286-292, 2004.

36. Zhang M, Dong W, Lu S, Yu Y, Liu H, Li G, Qiang W, Wang L and Lou J: Study on blood-gas changes in the coronary artery of myocardial ischemia reperfusion injury of rabbit. J Naval Med College 1: 9-12, 1996 (in Chinese).

37. Feng YJ, Chen C, Fallon JT, Lai T, Chen L, Knibbs DR, Waters DD and Wu AH: Comparison of cardiac troponin I, creatine kinase-MB, and myoglobin for detection of acute ischemic myocardial injury in a swine model. Am J Clin Pathol 110: 70-77, 1996.

38. Ishihara Y and Shimamoto N: Sulfaphenazole attenuates myocardial cell apoptosis accompanied with cardiac ischemia-reperfusion by suppressing the expression of BimEL and Noxa. J Pharmacol Sci 119: 251-259, 2012.

39. Qu D, Han J, Ren H, Yang W, Zhang X, Zheng Q and Wang D: Cardioprotective effects of Astragalin against myocardial ischemia/reperfusion injury in isolated rat heart. Oxid Med Cell Longev 2016: 8194690, 2016.

40. Pan H, Li D, Fang F, Chen D, Qi L, Zhang R, Xu T and Sun H: Salvianolic acid A demonstrates cardioprotective effects in rat hearts and cardiomyocytes after ischemia/reperfusion injury. J Cardiovasc Pharmacol 55: 535-542, 2011.

41. Zhang Q, Wang G, Yuan W, Wu J, Wang M and Li C: The effects of phosphodiesterase-5 inhibitor sildenafil against post-resuscitation myocardial and intestinal microcirculatory dysfunction by attenuating apoptosis and regulating microRNAs expression: Essential role of nitric oxide synthases signaling. J Transl Med 13: 177, 2015.

42. Wang ZG, Wang Y, Huang Y, Lu Q, Zheng L, Hu D, Feng WK, Liu YL, Ji KT, Zhang HY, et al: bFGF regulates autophagy and ubiquitinated protein accumulation induced by myocardial ischemia/reperfusion via the activation of the PI3K/Akt/mTOR pathway. Sci Rep 5: 9287, 2015.

43. Liu S, Ai Q, Feng K, Li YB and Liu X: The cardioprotective effect of dihydromyricetin prevents ischemia-reperfusion-induced apoptosis in vivo and in vitro via the PI3K/Akt and HIF-1α signaling pathways. Apoptosis 21: 1366-1385, 2016.

44. Zhou GJ, Wang W, Xie XM, Qin MJ, Kuii BK and Zhou TS: Post-harvest induced production of salvianolic acids and significant promotion of antioxidant properties in roots of *Salvia miltiorrhiza* (Danshen). Molecules 19: 7207-7222, 2014.

45. Fan G, Yu J, Asare PF, Wang L, Zhang H, Zhang B, Zhu Y and Gao X: Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling. J Cell Mol Med 20: 1908-1919, 2016.

46. Nagaoka K, Matoba T, Yao Y, Nakano Y, Ikeda G, Egusa S, Tokutome M, Nagahama R, Nakano K, Sunagawa K, et al: A new therapeutic modality for acute myocardial infarction: Nanoparticle-mediated delivery of Pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K/Akt pathway and anti-inflammation in a rat model. PLoS One 10: e0132451, 2015.